AHL
IKT icon

Abel Hall LLC’s Inhibikase Therapeutics IKT Stock Holding History

Abel Hall LLC’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94.1K Buy
46,352
+31,789
+218% +$56.9K 0.02% 843
2026
Q1 		$24.5K Buy
+14,563
New +$25.9K 0.01% 786

Other funds holding IKT

PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SIC
SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Abel Hall LLC's IKT Position: Q2 2026 in Review

Abel Hall LLC increased its Inhibikase Therapeutics (IKT) stake by 218% in Q2 2026, buying an estimated $56.9K and bringing the position to 46,352 shares worth $94.1K. The position accounts for 0.02% of the portfolio, ranked #843.

Abel Hall LLC first reported a position in IKT in Q1 2026 and has held it in 2 quarters since. 9 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Abel Hall LLC held 46,352 shares of Inhibikase Therapeutics worth $94.1K as of Q2 2026.
  • Abel Hall LLC bought 31,789 Inhibikase Therapeutics shares in Q2 2026, an estimated $56.9K.
  • Inhibikase Therapeutics made up 0.02% of Abel Hall LLC's portfolio in Q2 2026, its #843 holding.
  • Abel Hall LLC first reported a position in Inhibikase Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 9 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.